Difference between revisions of "Team:BGU Israel"
Line 48: | Line 48: | ||
<div id="Div1"> | <div id="Div1"> | ||
− | + | <div id="wikicontent-container"> | |
− | + | <div id="wikicontent"> | |
− | + | <br /> | |
− | + | <br /> | |
− | + | <ul class="bxslider"> | |
− | + | <li><img src="https://static.igem.org/mediawiki/2015/2/26/BGU_home_slider_team1.jpg" /></li> | |
− | + | <li><img src="https://static.igem.org/mediawiki/2015/a/a3/BGU_home_slider_team2.jpg" /></li> | |
− | + | <li><img src="https://static.igem.org/mediawiki/2015/4/42/BGU_home_slider_team3.jpg" /></li> | |
− | + | <li><img src="https://static.igem.org/mediawiki/2015/5/5c/BGU_home_slider_team4.jpg" /></li> | |
− | + | <li><img src="https://static.igem.org/mediawiki/2015/6/6a/BGU_home_slider_team5.jpg" /></li> | |
− | + | <li><img src="https://static.igem.org/mediawiki/2015/b/b6/BGU_home_slider_team6.jpg" /></li> | |
− | + | </ul> | |
− | + | ||
− | + | ||
− | + | ||
− | + | <div style="height: 145px; margin: 5px 0px 5px;"> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<table style="width: 100%; border-style: hidden;" > | <table style="width: 100%; border-style: hidden;" > | ||
− | + | <tr style="border-style: hidden;"> | |
− | + | <td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Achievements" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/1/17/BGU_home_icon_trophy.png" alt=""></a></div></td> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | <td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Description"><div align="center"><img src="https://static.igem.org/mediawiki/2015/3/3d/Bgu_project.png" alt=""></a></div></td> | |
− | + | <td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Design" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/6/6b/Bgu_brush-pencil.png" alt=""></a></div></td> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | <td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_IsraelResults"><div align="center"><img src="https://static.igem.org/mediawiki/2015/b/b0/Bgu_brightness.png" alt=""></a></div></td> | |
+ | <!-- https://static.igem.org/mediawiki/2015/b/b9/BGU_home_icon_briefcase.png --> | ||
− | + | <td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Practices" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/8/89/BGU_Rgb.png" alt=""></a></div></td> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
</tr> | </tr> | ||
<tr style="border-style: hidden;"> | <tr style="border-style: hidden;"> | ||
Line 130: | Line 88: | ||
<td style="text-align: left; border-style: hidden;"><div align="center">Results</div></td> | <td style="text-align: left; border-style: hidden;"><div align="center">Results</div></td> | ||
<td style="text-align: left; border-style: hidden;"><div align="center">Practices and Polices</div></td> | <td style="text-align: left; border-style: hidden;"><div align="center">Practices and Polices</div></td> | ||
− | + | ||
+ | |||
+ | </tr> | ||
+ | |||
</table> | </table> | ||
</div> | </div> | ||
<br /> | <br /> | ||
− | + | <h2> <span class="mw-headline" id="PhyscoFilter_.E2.80.93_Clean_different."> The Boomerang system: synthetic machine for cancer therapy </span></h2> | |
− | + | <p>Despite recent treatment advancements, cancer is still a major cause of mortality worldwide. One of the fundamental problems preventing the development of effective therapy is the difficulty to target cancer cells exclusively. | |
− | + | <br />In Boomerang, we're engineering a genetic device based on a simple concept of AND logic gate: the activation of our CRISPR/Cas9-based system is dependent on the existence of two cancer-specific promoters that control the expression of Cas9 and gRNA, and the combination of these two will occur only in cancer cells. CRISPR/Cas9 system allows several applications of Boomerang: 1) disruption of genes essential for cancer survival; and 2) activation of suicide genes, or color proteins for cancer cell detection (e.g., for complete surgical removal). <br />Our system can be potentially designed according to unique characteristics of a patient's tumor, paving the way to personalized medicine. We hope that our strategy will change the approach to cancer treatments.</p> | |
− | + | ||
− | + | ||
− | + | <br /><br /> | |
− | + | <!-- movie --> | |
− | + | <video width="900" controls> | |
− | + | <source src="https://static.igem.org/mediawiki/2015/6/65/IGEMbgu.mp4" type="video/mp4"> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</video> | </video> | ||
− | + | </p> | |
+ | <!-- movie --> | ||
− | + | <br /><br /> | |
− | + | ||
− | + | <!-- SPONSERS --> | |
<!-- | <!-- | ||
<h2> <span class="mw-headline" id="Sponsors"> Sponsors </span></h2> | <h2> <span class="mw-headline" id="Sponsors"> Sponsors </span></h2> | ||
Line 185: | Line 141: | ||
<!-- Map of entering the website from around the world --> | <!-- Map of entering the website from around the world --> | ||
− | + | <table> | |
− | + | <tr> | |
− | + | <td><div class="checklist" > | |
− | + | <div class="medal"> | |
− | + | <a href="https://2015.igem.org/Team:BGU_Israel/Achievements"> | |
− | + | <img src="https://static.igem.org/mediawiki/2015/b/b7/Medalcheck.png" height="150px" width="600px" /> | |
− | + | </a> | |
− | + | </div></div></td> | |
− | + | <td> | |
− | + | <center style="margin-top: 10px;"> | |
− | + | <div id="clustrmaps-widget"></div><script type="text/javascript"> var _clustrmaps = { 'url': 'https://2015.igem.org/Team:BGU_Israel', 'user': 1176746, 'server': '3', 'id': 'clustrmaps-widget', 'version': 1, 'date': '2015-08-19', 'lang': 'en', 'corners': 'square' }; (function () { var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www3.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x); })();</script><noscript><a href="http://www3.clustrmaps.com/user/9bc11f4aa" target="blank"><img src="http://www3.clustrmaps.com/stats/maps-no_clusters/2015.igem.org-Team-BGU_Israel-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript> | |
− | + | </center> | |
− | + | </td></tr></table> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
+ | </p> | ||
+ | </div> | ||
+ | </div> | ||
+ | <p> | ||
</div> | </div> |
Revision as of 08:30, 18 September 2015
The Boomerang system: synthetic machine for cancer therapy
Despite recent treatment advancements, cancer is still a major cause of mortality worldwide. One of the fundamental problems preventing the development of effective therapy is the difficulty to target cancer cells exclusively.
In Boomerang, we're engineering a genetic device based on a simple concept of AND logic gate: the activation of our CRISPR/Cas9-based system is dependent on the existence of two cancer-specific promoters that control the expression of Cas9 and gRNA, and the combination of these two will occur only in cancer cells. CRISPR/Cas9 system allows several applications of Boomerang: 1) disruption of genes essential for cancer survival; and 2) activation of suicide genes, or color proteins for cancer cell detection (e.g., for complete surgical removal).
Our system can be potentially designed according to unique characteristics of a patient's tumor, paving the way to personalized medicine. We hope that our strategy will change the approach to cancer treatments.
|
Follow us:
Address:
Ben Gurion 1, Beer Sheva 8410501, Israel
Mail: igembgu2015@gmail.com